This company listing is no longer active
DEVV Stock Overview
Bioscience Neutraceuticals, Inc. provides organic essential oil products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bioscience Neutraceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.00% |
| 3 Year Change | -99.99% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DEVV | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 0.9% |
| 1Y | -99.0% | -30.9% | 24.2% |
Return vs Industry: DEVV underperformed the US Personal Products industry which returned -20.9% over the past year.
Return vs Market: DEVV underperformed the US Market which returned -12.9% over the past year.
Price Volatility
| DEVV volatility | |
|---|---|
| DEVV Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DEVV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DEVV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Liang Chen | www.bestaromaoils.com |
Bioscience Neutraceuticals, Inc. provides organic essential oil products. The company is involved in repackaging and rebranding pure oils for sale to the end customers. Its product line consists of tea tree, eucalyptus, castor, rosehip, lemon, cinnamon, cedarwood, lemongrass, and emu oils.
Bioscience Neutraceuticals, Inc. Fundamentals Summary
| DEVV fundamental statistics | |
|---|---|
| Market cap | US$804.00 |
| Earnings (TTM) | -US$626.05k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs DEVV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DEVV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$626.05k |
| Earnings | -US$626.05k |
Last Reported Earnings
Dec 31, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DEVV perform over the long term?
See historical performance and comparison